Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

238.35
-9.3400-3.77%
Volume:577.03K
Turnover:138.40M
Market Cap:15.78B
PE:18.58
High:249.23
Open:249.23
Low:237.13
Close:247.69
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:0.71
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.83
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.57
PE(LYR):-53.95

Loading ...

Ascendis Pharma director Jean Jacques Bienaime acquires USD 111,986 in common shares

Reuters
·
Jun 02

Ascendis Pharma CFO Scott Thomas Smith acquires $55,830 of ordinary shares

Reuters
·
Jun 02

Ascendis Pharma director Jean Jacques Bienaime reports purchase of ordinary shares worth $95,120.5

Reuters
·
May 28

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading

MT Newswires Live
·
May 26

J.P. Morgan Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
May 20

Ascendis Pharma Initiated at Buy by Citigroup

Dow Jones
·
May 19

Assessing Ascendis Pharma (ASND) Valuation After Recent Soft Trading And Perceived Discount

Simply Wall St.
·
May 19

Ascendis Pharma initiated with a Buy at Citi

TIPRANKS
·
May 19

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

MT Newswires Live
·
May 18

Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
May 18

Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
May 16

Ascendis Pharma price target raised to $329 from $324 at Evercore ISI

TIPRANKS
·
May 15

Ascendis EVP Flemming Jensen sells 19,460 shares for $4.64 million

Reuters
·
May 13

Ascendis Pharma Is Maintained at Overweight by Barclays

Dow Jones
·
May 11

Ascendis Pharma price target raised to $345 from $342 at Barclays

TIPRANKS
·
May 11

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Becton Dickinson (BDX)

TIPRANKS
·
May 11

Ascendis Pharma (ASND) Gets a Buy from RBC Capital

TIPRANKS
·
May 08

Earnings Flash (ASND) Ascendis Pharma Posts Q1 Non-IFRS EPS 0.27 Euro

MT Newswires Live
·
May 07

Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate

Benzinga Earnings
·
May 07

Press Release: Ascendis Pharma Reports First Quarter 2026 Financial Results

Dow Jones
·
May 07